Investigational drug · Phase 3
SCTC21C
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE).
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "SCTC21C"
First trial start
2025
Jan 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCTC21C", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy
- Multiple Myeloma (MM)
- Systemic Lupus Erythematosus (SLE)
- Amyloidosis
Approved drugs for the same conditions: Multiple myeloma · Lupus (SLE) · IgA nephropathy · Hematology and blood cancers · Immunology and inflammation · Rare and genetic disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SCTC21C" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantPivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07297329 · 292 participants (planned) · Start Dec 29, 2025 · Primary completion Dec 2027
Drug: SCTC21C; Bortezomib and 2 more · For: Multiple Myeloma (MM)
Sites: Beijing, China
Sinocelltech Ltd.Industry
NCT07538154 · 159 participants (planned) · Start Apr 2026 · Primary completion Apr 2027
Drug: SCTC21C · For: Systemic Lupus Erythematosus (SLE)
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruiting
Sinocelltech Ltd.Industry
NCT06774664 · 99 participants (planned) · Start Jan 2025 · Primary completion Sep 2027
Drug: SCTC21C · For: IgA Nephropathy
Sites: Baotou, China; Beijing, China; Chengdu, China · 20 sites in all
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)Pivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07388602 · 90 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: SCTC21C; Bortezomib and 2 more · For: Amyloidosis
Sites: Beijing, China
Sinocelltech Ltd.Industry
NCT06252298 · 74 participants (planned) · Start Feb 28, 2024 · Primary completion Aug 28, 2025
Drug: SCTC21C · For: Relapsed or Refractory Hematologic Malignancies
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for IgA Nephropathy
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- FUB523zigakibart, BION-1301Phase 36 trials
Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- BHV-1400Phase 31 trial
Biohaven Therapeutics Ltd. · IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
- ADX-097Phase 21 trial
Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- CM338Phase 21 trial
Keymed Biosciences Co.Ltd · IgA Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.